Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

In a report released yesterday, Brian Abrahams from RBC Capital maintained a Buy rating on Regeneron (REGN – Research Report), with a price target of $1,240.00. The company’s shares closed ...

TD Cowen analyst Tyler Van Buren maintained a Buy rating on Regeneron (REGN – Research Report) today and set a price target of $1,030.00. The company’s shares closed yesterday at $686.33 ...

Regeneron Pharmaceuticals Inc. Annual stock financials by MarketWatch. View the latest REGN financial statements, income statements and financial ratios.